Skip to main content
. 2017 Aug 3;8(34):55863–55876. doi: 10.18632/oncotarget.19866

Figure 6. Protein interactions and stability of p85 cSH2 exchange mutants.

Figure 6

A. Co-immunoprecipitation of p110α with HA-tagged p85β, p85β/αcSH2, p85α and p85α/βcSH2. p110α interacts with wild type p85α, p85β and the cSH2 exchange mutants. B. Cycloheximide (50 μg/ml) treatment of p85α, p85β and the cSH2 exchange mutants. The Western blot indicates the protein expression level during cycloheximide (50 μg/ml) treatment compared to GAPDH as a control. C. Time course of p85 and exchange mutant degradation as determined by cycloheximide treatment.